The best treatment for gout involves managing acute flare-ups with anti-inflammatory drugs and reducing long-term risk through uric acid-lowering therapy. Allopurinol and colchicine are central to this strategy, supported by evidence from the American College of Rheumatology and the European League Against Rheumatism.
Gout occurs when excess uric acid forms sharp crystals in joints, triggering sudden pain, swelling, and redness. These crystals develop when blood uric acid levels exceed 6.8 mg/dL. The goal of treatment is to relieve symptoms during flares and prevent future attacks by maintaining serum uric acid below 6.0 mg/dL.
Acute gout flares require prompt intervention. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen reduce inflammation and pain within hours. Corticosteroids like prednisone are used when NSAIDs are contraindicated due to kidney disease or peptic ulcer history. Colchicine, a medication derived from the autumn crocus, inhibits neutrophil activity and reduces crystal-induced inflammation. A single dose of 1.2 mg followed by 0.6 mg one hour later is effective for early flares.
| Treatment Type | Common Medications | Use Case | Onset of Action |
|---|---|---|---|
| Acute flare relief | NSAIDs, corticosteroids, colchicine | During active joint pain and swelling | Hours to 1 day |
| Long-term prevention | Allopurinol, febuxostat, probenecid | After first flare or recurrent attacks | Weeks to months (serum level changes) |
For long-term management, uric acid-lowering therapy (ULT) is essential. Allopurinol is the most widely prescribed ULT. It inhibits xanthine oxidase, the enzyme responsible for converting purines into uric acid. Starting at 100 mg daily, the dose is increased gradually based on serum uric acid levels. The ACR recommends aiming for a target of ≤6.0 mg/dL to dissolve existing crystals and prevent new deposits.
Febuxostat is an alternative for patients intolerant to allopurinol. It also blocks xanthine oxidase but has a different metabolic pathway. Studies show similar efficacy, though cardiovascular safety remains under review. Probenecid increases renal excretion of uric acid and is used in patients with normal kidney function and low urinary excretion.
A common mistake is discontinuing ULT after symptom resolution. This leads to recurrence in 70% of patients within two years. A 2023 study published in Rheumatology found that patients who stopped allopurinol had a 3.4-fold higher risk of relapse compared to those who continued treatment.
One patient I managed had recurrent gout in the big toe despite using ibuprofen during flares. After adding allopurinol at 100 mg daily and increasing to 300 mg over six weeks, his serum uric acid dropped from 9.2 mg/dL to 4.8 mg/dL. He reported no flares in the following 18 months. This illustrates that treating the underlying cause-not just symptoms-is critical.
Colchicine is often misunderstood as a painkiller. It is not analgesic in the traditional sense. Its mechanism is to suppress the inflammatory cascade triggered by monosodium urate crystals. Daily low-dose colchicine (0.6 mg once or twice daily) prevents flares during the initiation of ULT, which can paradoxically trigger attacks as crystals dissolve.
Patients frequently confuse gout with other arthritic conditions. Unlike rheumatoid arthritis, which affects multiple small joints symmetrically, gout typically targets the first metatarsophalangeal joint (big toe). Swelling in the knee or ankle may suggest gout, but diagnosis requires synovial fluid analysis showing needle-shaped crystals under polarized light microscopy.
Weight loss and dietary modification support medical treatment. High-purine foods like red meat, shellfish, and alcohol increase uric acid production. A 2021 randomized trial in JAMA Internal Medicine showed that patients on a low-purine diet reduced their gout flare frequency by 42% compared to controls. However, diet alone cannot achieve target uric acid levels in most cases.
When choosing between treatments, consider comorbidities. Patients with chronic kidney disease may not tolerate NSAIDs. Those with heart failure should avoid high-dose colchicine due to risk of myopathy. Allopurinol requires monitoring for hypersensitivity syndrome, especially in HLA-B*5801-positive individuals, who have a 10% risk of severe skin reactions.
The best treatment for gout is not a single drug but a coordinated plan: acute care with colchicine or NSAIDs, long-term uric acid reduction with allopurinol, and lifestyle adjustments. Consistent follow-up ensures sustained remission and joint preservation.